X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Approval of Two New Prostate Cancer Drugs Gives Patients and Families Hope

/ /

MEDIA CONTACT:
Ilana Ostrin
202-657-2249
ilana@zerocancer.org

Approval of Two New Prostate Cancer Drugs Gives Patients and Families Hope
In the span of a week, the FDA permits two new drugs for advanced prostate cancer patients to move to market

Washington, D.C., May 20, 2020 — It’s a thrill for prostate cancer advocates when a new treatment moves from the research bench to the patient’s bedside. When this occurs, hope ripples across the cancer community. Lightning struck twice this week for the prostate cancer community, as the FDA approved olaparib (LYNPARZA) for patients with metastatic castration-resistant prostate cancer (mCRPC). The news comes only days after the agency approved another drug (Rubraca) that is also targeted to mCRPC patients.

“This news gives patients double the hope as we now have more novel solutions for fighting advanced prostate cancer,” Jamie Bearse, ZERO’s CEO, said. “Now patients have the option of another completely new pharmacological treatment, which has greatly improved outcomes for patients in studies. This is a great example of how we can target treatments based on precision medicine results. It’s exciting to think that future similar advancements will continue to develop and progress to battle prostate cancer.”

Olaparib is targeted to patients who have deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations and have progressed following prior treatment with a new hormonal agent. LYNPARZA is jointly developed and commercialized by AstraZeneca and Merck & Co., Inc. Foundation Medicine served as the Next-Generation Sequencing partner.

For more on olaparib and its study findings, click here.

                                                            ###

About ZERO — The End of Prostate Cancer

ZERO — The End of Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action. We’re building Generation ZERO, the first generation of men free from prostate cancer, through our national run/walk series, education and patient support programs, and grassroots advocacy. ZERO is a 501(c)(3) philanthropic organization recognized with four out of four stars by Charity Navigator, accredited by the Better Business Bureau, with regional chapters across the country. We dedicate 86 cents of every dollar to research and programs. For more information, visit www.zerocancer.org.